30 September 2026

HARGREAVE HALE AIM VCT PLC
(the “Company”)

Allotment of Shares under DRIS

The Company has today allotted 990,800 Ordinary Shares pursuant to its Dividend Reinvestment Scheme (“DRIS”) to Shareholders of the Company who elected to receive Ordinary Shares instead of the special dividend of 0.75 pence per Ordinary Share, paid today.

The price at which the 990,800 Ordinary Shares were allotted was 31.50 pence per Ordinary Share, which was calculated, in accordance with the terms and conditions of the DRIS, on the basis of the last published ex-dividend net asset value per Ordinary Share in the Company as at the close of business on 16 September 2026. The DRIS issue price was announced on 17 September 2026.

Application for the new shares to be admitted to the Official List of the Financial Conduct Authority and to trading on London Stock Exchange plc’s main market for listed securities has been made and dealings are expected to commence on or around 7 October 2026.

As a Person Discharging Managerial Responsibility (“PDMR”), the following director of the Company, and his Persons Closely Associated, (“PCA”) were allotted shares at a price of 31.50 pence:

Name No. of Shares allotted Holding following Allotment Percentage of Issued Share Capital held
Justin WARD (PDMR) 1,461 62,786  
0.02%
 
Elizabeth WARD (PCA) 569 24,481

Further information regarding the DRIS offered in respect of the Dividends can be found in the DRIS Mandate (the “DRIS Mandate“) available on the Company’s website to view and/or download at https://www.hargreaveaimvcts.co.uk/document-library/. The DRIS Mandate is also available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

As a result of the issue, the total number of Ordinary Shares in issue will be 375,295,536 with each Ordinary Share carrying one vote each. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total voting rights in the Company will be 375,295,536. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

END

For further information, please contact:

Canaccord Genuity Asset Management Limited
Abbe Martineau
 
aimvct@canaccord.com
+44 207 523 4525  
 

LEI: 213800LRYA19A69SIT31        

  • In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients
  • Denifanstat showed progressive and sustained improvements across all efficacy endpoints in the OLE, including Investigator’s Global Assessment (IGA) success with a response rate of 57%, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-tolerated, with no adverse event-related permanent discontinuations
  • Patient screening for AURORA U.S. Phase 3 clinical trial expected to begin in October 2026
  • Sagimet to host a KOL event and webcast September 30, 2026 at 1 PM ET

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. (Ascletis) in China. The results were presented at the European Academy of Dermatology and Venereology Congress (EADV) in Vienna by Ascletis. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world.

The Phase 3 OLE clinical trial, ASC40-304, evaluated the long-term safety of denifanstat in patients with moderate to severe acne vulgaris who were previously enrolled in the 12-week randomized, double-blind, placebo-controlled Phase 3 ASC40-303 clinical trial, conducted in China by Ascletis. 240 patients rolled over into the OLE trial, for a total trial duration of up to 52 weeks. 116 of those patients had received denifanstat, and 124 patients had received placebo in the original 12-week double-blind ASC40-303 trial. Primary endpoints evaluated safety, and secondary endpoints evaluated efficacy, including reduction in IGA from baseline and reduction in total lesion count and inflammatory lesion count from baseline.

Phase 3 Open-Label Extension Results

The baseline characteristics of the OLE cohorts were consistent with the overall study population, as shown below:

Baseline Characteristics of ASC40-304 OLE Cohorts at ASC40-303 Baseline

Baseline Characteristics ASC40-304
Denifanstat/Denifanstat
(n=116)
ASC40-304
Placebo/Denifanstat
(n=124)
ASC40-303 Total
(n=480)
Age, years, mean (SD) 22.5 (4.1) 22.3 (3.3) 22.6 (3.8)
Male, n (%) 31 (26.7) 47 (37.9) 150 (31.3)
Female, n (%) 85 (73.3) 77 (62.1) 330 (68.8)
IGA=3 (moderate), n (%) 101 (87.1) 106 (85.5) 412 (85.8)
IGA=4 (severe), n (%) 15 (12.9) 18 (14.5) 68 (14.2)
Total lesion count, mean (SD) 102.8 (25.3) 103.2 (24.4) 102.1 (24.8)
Inflammatory lesion count, mean (SD) 42.0 (12.2) 43.5 (11.8) 42.6 (11.9)
Non-Inflammatory lesion count, mean (SD) 60.8 (19.3) 59.7 (20.9) 59.5 (19.9)

Treatment success was defined as at least a 2-point reduction from baseline in Investigator’s Global Assessment (IGA) score with a score of 0 (clear) or 1 (almost clear). At the end of the trial, treatment success rates and mean percentage changes, compared to the ASC40-303 baseline, were:

Efficacy Endpoints Denifanstat 12wk /
Denifanstat 40wk
(n=116)
Placebo 12wk /
Denifanstat 40wk
(n=124)
Total (n=240)
Treatment success rate 57.8% 55.6% 56.7%
Mean % change in total lesion count -73.0% -70.7% -71.8%
Mean % change in inflammatory lesion count -78.1% -75.8% -76.9%
Mean % change in non-inflammatory lesion count -68.3% -65.5% -66.9%


Note: Total skin lesion counts and inflammatory skin lesion counts reduced by approximately 75% and 80%, respectively, compared to ASC40-303 baseline for patients who completed the OLE trial.

Denifanstat was generally well-tolerated in the OLE with patients receiving up to 52 weeks of exposure, with no permanent discontinuations of study drug due to adverse events and no drug-related serious adverse events among patients treated with denifanstat. Only two categories of treatment-related adverse events had an incidence of more than 5% over the 52-week period: dry skin in 7.1% and dry eye in 5.9%.

“The positive results presented today at EADV reinforce our confidence in denifanstat as we prepare to begin patient screening for our U.S. AURORA Phase 3 clinical trial in October, with first patient enrollment expected shortly thereafter,” said David Happel, Chief Executive Officer of Sagimet. “Annually approximately ten million people in the U.S. live with moderate to severe acne. Denifanstat, if approved, could offer a convenient, once-daily oral medication for this underserved patient population, and would be the first oral treatment with a novel mechanism of action approved for acne in more than forty years.”

“The open-label extension trial provides important data to support our AURORA Phase 3 program,” said Andreas Grauer, MD, Chief Medical Officer of Sagimet. “It is particularly encouraging that patients continued to improve with longer treatment, and denifanstat remained generally well-tolerated through the open-label extension trial, with exposure to denifanstat up to 52 weeks. Notably, patients who crossed over from placebo achieved treatment success rates similar to those treated with denifanstat from the start. Together, these results provide meaningful long-term experience with the 50 mg denifanstat dose we are taking forward in AURORA.”

Virtual Key Opinion Leader Conference Call Information

Sagimet Biosciences will host a virtual KOL event with Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society on September 30, 2026 at 1 PM ET.

Dr. Harper will join company management for a review of the 52-week data from license partner Ascletis’ Phase 3 open-label extension clinical trial of denifanstat in moderate to severe acne vulgaris in China and an update on the company’s planned U.S. Phase 3 AURORA clinical trial of denifanstat for the treatment of moderate to severe acne. Live webcast available: LINK

About the Ascletis Phase 3 Clinical Trial and Open-Label Extension

ASC40-303 (NCT06192264) was a randomized, double-blind, placebo-controlled 12-week Phase 3 clinical trial of denifanstat in 480 patients with moderate to severe acne vulgaris, conducted in China by Ascletis. Patients were randomized 1:1 to denifanstat 50 mg or placebo once daily. Denifanstat met all primary and secondary endpoints and was generally well-tolerated.

ASC40-304 (NCT06248008) was a multi-center, open-label Phase 3 extension evaluating the long-term safety of denifanstat in patients with moderate to severe acne vulgaris who were previously enrolled in the double-blind, randomized, placebo-controlled 12-week Phase 3 ASC40-303 trial. This open-label Phase 3 trial enrolled 240 subjects that received oral denifanstat 50 mg once daily for up to 40 weeks. Subjects who were originally randomized to denifanstat in ASC40-303 trial had a total of up to 52 weeks of denifanstat exposure. Primary endpoints evaluated safety, and secondary endpoints evaluated efficacy, including reduction in IGA from baseline and reduction in total lesion count and inflammatory lesion count from baseline for up to 52 weeks of denifanstat treatment. Denifanstat was generally well-tolerated. Subjects treated with denifanstat showed improvements in all efficacy endpoints (secondary endpoints of the trial) beyond those observed at 12 weeks. 

About the AURORA Phase 3 Clinical Trial

The AURORA multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial of denifanstat in moderate to severe acne is intended to enroll approximately 800 U.S. patients aged 12 years and older, of which 450 are expected to be adolescents aged 12 to 17 years. Patients will be randomized 2:1 to receive denifanstat 50 mg or placebo once daily for 12 weeks. The trial will have three co-primary endpoints that will be assessed at week 12: the proportion of patients achieving treatment success in a global assessment score, defined as at least a 2-point reduction from baseline with a score of 0 (clear) or 1 (almost clear); absolute change in inflammatory skin lesion counts from baseline; and absolute change in non-inflammatory skin lesion counts from baseline. A subset of approximately 530 patients completing the double-blind period will be eligible to enter a 40-week open-label extension evaluating the long-term safety of denifanstat.

About Denifanstat

Denifanstat is an oral, once-daily FASN inhibitor in development for the treatment of moderate to severe acne. In trials conducted by Sagimet’s license partner, Ascletis BioScience Co. Ltd. (Ascletis) in China, denifanstat met all primary and secondary endpoints in a 12 week randomized, double-blind Phase 3 clinical trial in moderate to severe acne vulgaris and was generally well-tolerated and showed improvements in all efficacy endpoints measured at 52 weeks (secondary endpoints of the trial) in an open-label extension clinical trial evaluating denifanstat’s long-term safety in patients with moderate to severe acne. Denifanstat is being developed by Ascletis as ASC40 for acne in China and by Sagimet in the rest of world.

About Acne

Acne is one of the most common skin conditions in the U.S., with approximately 50 million Americans affected annually and more than 5 million seeking medical treatment for acne each year. Acne affects around 85% of persons between the ages of 12 and 24. Moderate to severe acne accounts for 20% of acne sufferers, or approximately 10 million people in the U.S. annually. There is no cure for acne, and due to its pathology, most patients require chronic management and multiple annual courses of treatment for flare control.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development and registration efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

Multiple scheduled demonstrations across North America, Europe and Asia will showcase VARAN unmanned ground vehicles, drone technologies and integrated autonomous systems to prospective defense customers

WEST HOLLYWOOD, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a defense technology and advanced autonomous systems company, today announced an expanded international demonstration and customer-evaluation program for its autonomous ground, aerial and sensing technologies.

Over the coming months, VisionWave is scheduled to conduct multiple demonstrations and technical evaluations across North America, Europe and Asia, involving the Company’s VARAN unmanned ground vehicle, unmanned aerial systems, drone technologies, intelligence, surveillance and reconnaissance (“ISR”), sensing technologies and integrated air-ground capabilities.

The demonstrations are being organized for prospective defense and security customers, strategic defense partners and systems integrators and are intended to allow participants to evaluate VisionWave technologies against specific operational requirements and mission profiles.

The program represents an important next phase in VisionWave’s strategy of moving its autonomous defense technologies from development into direct customer evaluation.

Putting VisionWave Technology in Front of Defense Customers

VisionWave’s demonstration program is designed around direct, hands-on evaluation of its technologies.

Rather than limiting customer engagement to presentations and technical discussions, the Company is working to place its systems in operational demonstration environments where prospective customers and partners can evaluate mobility, sensing, autonomous capabilities, payload integration and potential mission configurations.

The current program includes demonstrations of VARAN unmanned ground vehicles, drone technologies and combined ground-and-aerial capabilities, with different demonstrations structured around the requirements and areas of interest of the participating organizations.

Several demonstrations are scheduled during the fourth quarter of 2026, creating a concentrated period of international customer engagement across VisionWave’s autonomous systems portfolio.

“This is about putting our technology in the field and in front of the organizations that evaluate and deploy defense systems,” said Douglas Davis, Chief Executive Officer of VisionWave. “We now have a meaningful schedule of demonstrations and customer evaluations across several international markets. These are opportunities for prospective customers to see the technology operate, evaluate it against their requirements and engage directly with our technical and business-development teams.”

“Our objective is to move from demonstration to evaluation, from evaluation to a customer-defined configuration and, if a customer elects to proceed, toward procurement. There is no assurance that any demonstration will lead to an order.”

VARAN at the Center of the Demonstration Program

A significant portion of VisionWave’s upcoming demonstration activity will feature VARAN, the Company’s heavy wheeled unmanned ground vehicle under development as part of the STRATUM family of autonomous ground systems. VARAN has not completed qualification testing and is not in production.

VARAN is being developed around a modular, payload-agnostic architecture intended to support multiple defense and security applications from a common autonomous ground platform.

Potential configurations include ISR, autonomous logistics and resupply, radar and RF sensing, remote weapon stations, drone launch and recovery, communications and sensor payloads, counter-UAS and force-protection applications and other customer-specific mission systems.

The modular architecture is intended to allow VisionWave to demonstrate the same core platform to different prospective customers while configuring sensors, payloads and mission systems around their individual operational requirements.

VisionWave is also advancing unmanned aerial systems and drone-related technologies, including demonstrations involving aerial systems independently and in combination with autonomous ground technologies.

Building on VisionWave’s First STRATUM Conditional Purchase Order

The scheduled demonstrations follow the Company’s announcement of its receipt of a conditional purchase order from Metal Machinery Components Trading FZCO, a trading intermediary, for the STRATUM platform, covering 200 VARAN unmanned ground vehicles with an aggregate base purchase price of $20 million.

As previously disclosed, the purchase order is subject to conditions precedent.

VisionWave views the purchase order as one component of a broader commercialization effort now underway across its autonomous defense technology portfolio. The Company’s immediate commercial focus extends beyond any single transaction and includes expanding the number of prospective customers directly evaluating VisionWave technologies.

Modular System Architecture

VisionWave’s autonomous systems strategy is to combine unmanned ground vehicles, unmanned aerial systems, ISR, RF sensing and mission intelligence.

The Company is developing its technologies around a modular approach intended to enable ground vehicles, aerial systems, sensors and mission payloads to operate independently or as components of integrated autonomous systems.

Additional Demonstration Activity

VisionWave expects its demonstration and evaluation activities to continue across multiple international markets as the Company seeks to develop its global business-development pipeline.

The currently planned activities span North America, Europe and Asia and include prospective government, military and defense-industry participants.

The Company believes the breadth of these engagements provides an opportunity not only to demonstrate individual technologies, but also to obtain direct operational feedback that can inform product development, customer-specific configurations and future commercial opportunities.

Demonstrations and evaluations do not constitute purchase orders or commitments and may not result in commercial orders. Any future procurement would depend on customer decisions and applicable procurement, export, regulatory and other requirements.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies intended for use across air, land and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission. The platforms, payloads, sensing technologies and software described in this press release, including the STRATUM family and the VARAN unmanned ground vehicle, are in development, have not completed testing or qualification, are not commercially available and have not generated material revenue.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact, including statements regarding the satisfaction of the conditions precedent to the VARAN purchase order; the timing and outcome of the demonstration contemplated for October or November 2026 under the purchase order; the number, timing, scope and outcome of the other demonstrations and evaluations described in this press release; the negotiation of a technical annex and any resulting price adjustment; production planning and delivery; the Company’s other demonstration and evaluation activities and whether any of them will result in an order; the development, qualification and capabilities of the STRATUM, VARAN, RANGER, SCOUT and RECON platforms and the Company’s unmanned aerial and ISR technologies; and the Company’s strategy and objectives. Words such as “scheduled,” “intends,” “expects,” “contemplates,” “believes,” “designed to,” “intended to,” “potential,” “may,” “will,” “objective” and similar expressions identify forward-looking statements.

These statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including: the Customer’s ability to deliver proof of funds and a bank guarantee acceptable to the Company and to make the advance and milestone payments; the receipt of export licenses and end-user approvals in each relevant jurisdiction and the results of the Company’s sanctions, anti-money-laundering and end-user review, including with respect to end users located in or near conflict zones; the Company’s approval, or withdrawal of approval, of any end user; the results of the demonstration and the effect of end-user requirements, localization, tariffs and component costs on the base configuration and unit price; the Company’s ability to establish manufacturing capacity and to complete qualification testing of the VARAN platform; the Company’s dependence on a single conditional order from a trading intermediary; the fact that the Company’s other demonstration and evaluation activities are not the subject of any contract or commitment and may not result in orders; the lengthy and uncertain nature of defense procurement processes and the discretion of prospective customers; the possibility that scheduled demonstrations are postponed or cancelled or that the Company’s systems fail to perform as intended during a demonstration; the Company’s ability to obtain any export licenses required to transport and demonstrate its systems outside the United States; the Company’s limited operating history, history of losses and need for additional financing, which may be dilutive to stockholders; and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, [2025] and in its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

investors@vwav.inc

RIDGELAND, Miss., Sept. 30, 2026 (GLOBE NEWSWIRE) — Cal-Maine Foods, Inc. (Nasdaq: CALM) (“Cal-Maine Foods,” “we,” “us,” “our” or the “company”), the largest egg company in the United States and a leading player in the egg-based food industry, today reported results for its first quarter ended August 29, 2026. Unless otherwise indicated, all comparisons are to the comparable period of fiscal 2026.

Financial Highlights

  (in thousands except per share amounts and percentages)
  First Quarter
  2027     2026   $ Change   % Change
Net sales $ 539,607     $ 922,602   $ (382,995 )   (41.5 ) %
Gross profit $ 403     $ 311,314   $ (310,911 )   (99.9 ) %
Operating income (loss) $ (82,165 )   $ 249,184   $ (331,349 )   (133.0 ) %
Net income (loss) attributable to Cal-Maine Foods, Inc. $ (58,615 )   $ 199,340   $ (257,955 )   (129.4 ) %
Income (loss) per share – diluted $ (1.26 )   $ 4.12   $ (5.38 )   (130.6 ) %


Strategic Execution Highlights

  • Continued focus on sales diversification and mix shift, expected to strengthen earnings durability and predictability over time
    • In the first quarter of fiscal 2027:
      • Prepared Foods accounted for 11.7% of net sales compared to 7.8%
      • Combined, Specialty Shell Eggs and Prepared Foods increased to 54.1% of net sales compared to 37.1%
  • Acquired additional Eggland’s Best® franchise territory in Northeast, expanding the company’s distribution footprint and increasing its Specialty Shell Eggs category penetration across one of the nation’s largest, highest-income consumer markets
  • Continued progress on previously announced projects to increase efficiency and production capacity, which are expected to increase Prepared Foods production capacity more than 60% by the first half of fiscal 2028, compared to fiscal 2026 year-end

Commentary

Sherman Miller, president and chief executive officer of Cal-Maine Foods, said, “Our first-quarter results reflect both the current point in the conventional shell egg cycle and the continued evolution of Cal-Maine Foods’ earnings model. Conventional Shell Egg pricing remains under pressure from an industry supply imbalance, while underlying demand remains healthy. At the same time, Specialty Shell Eggs and Prepared Foods now represent approximately 54% of our net sales, demonstrating the progress we have made in broadening our business. We remain focused on our foundational Conventional Shell Egg business while scaling Specialty and Prepared Foods and converting the investments we have made into profitable growth.”
Segment Results Summary

  Segment Net Sales
  (in thousands except percentages)
  First Quarter
  2027     2026     Volume
Change
  Avg.
Price
Change
Conventional Shell Eggs $ 201,683     $ 498,433     (0.7 ) %   (59.3 ) %
Specialty Shell Eggs   236,932       275,590     (3.8 ) %   (10.7 ) %
Prepared Foods   62,995       72,368     (19.3 ) %   7.9   %
Total Reportable Segments $ 501,610     $ 846,391              

  Operating Income (Loss)
  (in thousands except percentages)
  First Quarter
              Operating Margin
  2027     2026     2027   2026
Conventional Shell Eggs $ (71,045 )   $ 168,236     (35.2 ) %   33.8   %
Specialty Shell Eggs   14,937       64,196     6.3   %   23.3   %
Prepared Foods   7,842       13,221     12.4   %   18.3   %
Total Reportable Segments $ (48,266 )   $ 245,653     (9.6 ) %   29.0   %
Other – Segment Income (Loss)   (8,374 )     12,219     N/A     N/A    
Unallocated Corporate SG&A   (24,609 )     (16,072 )   N/A     N/A    
Gain on Involuntary Conversion   —       7,488     N/A     N/A    
Loss on Disposal of Fixed Assets   (916 )     (104 )   N/A     N/A    
Operating Income (Loss) $ (82,165 )   $ 249,184     (15.2 ) %   27.0   %

N/A – Not Applicable

Conventional Shell Eggs

First-quarter performance reflected an abundantly supplied egg market following industry layer flock repopulation during fiscal 2026. The increase in egg supply, together with the first quarter’s historically softer seasonal pricing, resulted in substantially lower conventional shell egg prices compared with the prior-year period.

Conventional Shell Eggs sales decreased 59.5%, primarily reflecting a 59.3% decrease in average selling price per dozen, while volume remained relatively flat. The effect of lower market prices was partially mitigated by hybrid and cost-plus pricing arrangements with certain customers. Segment loss was $71.0 million, compared with segment income of $168.2 million in the prior-year period, as lower pricing more than offset lower outside egg purchase costs.

Specialty Shell Eggs

Specialty Shell Eggs sales decreased 14.0%, reflecting a 10.7% decrease in average selling price per dozen and a 3.8% decrease in volume. The prior-year period benefited from atypical pricing relationships between conventional and specialty shell eggs that temporarily accelerated demand for certain specialty shell egg categories. During the current quarter, lower volumes reflected a more typical demand relationship across the conventional and specialty shell egg categories.

Segment income was $14.9 million, compared with $64.2 million in the prior-year period, primarily due to lower selling prices and higher cost per dozen resulting from increased feed and production costs, partially offset by lower selling, general and administrative expense.

Prepared Foods

Prepared Foods sales decreased 13.0% reflecting a 19.3% decrease in pounds sold, primarily related to temporary production reductions during capacity expansion and network optimization activities, which was partially offset by a 7.9% increase in average selling price per pound. Segment income was $7.8 million, compared with $13.2 million in the prior-year period. We continue to advance our previously announced production capacity and optimization projects to support future growth and improved operating efficiency.

Outlook

Mr. Miller commented, “Looking ahead, there are two important timing dynamics: when the conventional shell egg market begins to rebalance and when our investments in Prepared Foods translate into greater earnings contribution. We cannot precisely predict the first, but we have considerably greater visibility into the second. Current earnings reflect a difficult point in the commodity cycle while we are simultaneously investing ahead of growth, and we do not believe that fully reflects the through-cycle earnings power we are building. With a strong balance sheet, more than 60% planned growth in Prepared Foods capacity through the first half of fiscal 2028, and continued opportunities across Specialty Shell Eggs, we are well positioned to invest through the cycle and build a more diversified and durable earnings profile.”

Share Repurchase Update

Cal-Maine Foods repurchased 66,601 shares of its common stock under the company’s current share repurchase authorization during the first quarter of fiscal 2027 for a total of $5.0 million. The repurchase program permits the company to repurchase up to $500 million, of which $315.7 million remained available as of the end of the first quarter of fiscal 2027. Subsequent to the end of the first quarter, Cal-Maine Foods repurchased 204,888 shares under the repurchase program for $14.9 million.

Dividend Payment

Pursuant to the company’s variable dividend policy, Cal-Maine Foods will not pay a cash dividend with respect to the first quarter of fiscal 2027. The company will not pay a dividend for a subsequent profitable quarter until it is profitable on a cumulative basis computed from the date of the last quarter in which a dividend was paid. As of August 29, 2026, the cumulative loss to be recovered before payment of any future dividend under the variable dividend policy was $94.5 million.

Conference Call and Webcast

Management will host a conference call and webcast at 9:00 a.m. ET on September 30, 2026. Participants can access the live webcast on the Investor Relations page of the Cal-Maine Foods website at https://www.calmainefoods.com/events-presentations. To join by telephone, participants can register here. Upon registration, participants will receive a confirmation email with detailed instructions, including a dial-in number, unique passcode, and registrant ID. A replay of the webcast will be available for 30 days following the call on the Investor Relations page of the Cal-Maine Foods website at https://www.calmainefoods.com/events-presentations.

About Cal-Maine Foods

Cal-Maine Foods, Inc. (Nasdaq: CALM) is the largest egg company in the United States and a leading player in the egg-based food industry. With a strong national footprint, Cal-Maine Foods provides nutritious, affordable, and sustainable protein to millions of households every day.

The company’s portfolio spans the full egg value ladder—from conventional to specialty, including cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs—serving retail, foodservice and industrial customers nationwide. Cal-Maine Foods also participates in the growing prepared foods sector, with offerings such as pre-cooked egg patties, omelets, folded and scrambled egg formats, hard-cooked eggs, pancakes, waffles, and specialty wraps. Its branded portfolio includes Eggland’s Best®, Land O’Lakes®, Farmhouse Eggs®, 4Grain®, Sunups®, Sunny Meadow®, MeadowCreek Foods®, Van’s®, and Crepini®.

Headquartered in Ridgeland, Mississippi, Cal-Maine’s strategy combines scale, operational excellence, and financial discipline with a commitment to innovation and sustainability, to enable the company to deliver trusted nutrition, enduring partnerships, and long-term value for its stakeholders.

Forward Looking Statements

Statements contained in this press release that are not historical facts are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current intent, belief, expectations, estimates and projections regarding our Company and our industry. These statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that are difficult to predict and may be beyond our control. The factors that could cause actual results to differ materially from those projected in the forward-looking statements include, among others, (i) changes in wholesale shell egg market prices, (ii) changes in the demand for shell eggs and our prepared foods offerings, (iii) increases in feed costs for our shell egg operations as well as increases in input costs for prepared foods, (iv) our ability to predict and meet demand for cage-free and other specialty shell eggs, (v) the risks and hazards inherent in shell egg, egg products and prepared foods operations (including, as applicable, disease, pests, weather conditions, and potential for product recall), including but not limited to the current outbreak of HPAI affecting poultry in the U.S., Canada and other countries that was first detected in commercial flocks in the U.S. in February 2022 and that impacted our flocks in the third and fourth quarters of fiscal 2024 and again in March 2026, (vi) risks, changes, or obligations that could result from our recent or future acquisition of new flocks or businesses, such as our acquisition of Echo Lake Foods completed June 2, 2025, and risks or changes that may cause conditions to completing a pending acquisition not to be met, (vii) our ability to successfully integrate and manage recently acquired businesses, like Echo Lake Foods, and realize the expected benefits of such acquisitions, including synergies, cost savings, reduction in earnings volatility, margin expansion, financial returns, expanded customer relationships, or sales or growth opportunities, (viii) our ability to produce, supply and distribute shell eggs and prepared foods efficiently and reliably, (ix) our ability to compete effectively with existing competitors and new market entrants, retain existing customers, acquire new customers and grow our product mix including our prepared foods product offerings, (x) the impacts of government, customer and consumer reactions to high market prices for eggs, including, without limitation, potential new or expanded government regulations, (xi) risks relating to potential changes in inflation, interest rates and trade and tariff policies, (xii) the loss or expiration of any registered trademarks or other intellectual property that we use in our business, (xiii) adverse results in pending litigation and other legal matters, (xiv) global instability, including as a result of geopolitical conflicts and other uncertainties and (xv) the risk factors set forth the company’s SEC Filings (including its Annual Report on Form 10-K, as may be updated by the company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). The Company’s SEC filings may be obtained from the SEC or the company’s website, www.calmainefoods.com. Readers are cautioned not to place undue reliance on forward-looking statements because, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. Further, forward-looking statements included herein are made only as of the respective dates thereof, or if no date is stated, as of the date hereof. Except as otherwise required by law, we disclaim any intent or obligation to update publicly these forward-looking statements, whether because of new information, future events, or otherwise.

CAL-MAINE FOODS, INC. AND SUBSIDIARIES
FINANCIAL HIGHLIGHTS
(Unaudited)
(In thousands, except per share amounts)
 
SUMMARY STATEMENTS OF OPERATIONS
 
    13 Weeks Ended
    August 29, 2026   August 30, 2025
Net sales   $ 539,607     $ 922,602  
Cost of sales     539,204       611,288  
Gross profit     403       311,314  
Selling, general and administrative     81,652       69,514  
Gain on involuntary conversions     —       (7,488 )
Loss on disposal of fixed assets     916       104  
Operating income (loss)     (82,165 )     249,184  
Other income, net     7,969       14,081  
Income (loss) before income taxes     (74,196 )     263,265  
Income tax expense (benefit)     (17,992 )     64,158  
Net income (loss)     (56,204 )     199,107  
Less: Income (loss) attributable to noncontrolling interest     2,411       (233 )
Net income (loss) attributable to Cal-Maine Foods, Inc.   $ (58,615 )   $ 199,340  
             
Net income (loss) per common share:            
Basic   $ (1.26 )   $ 4.13  
Diluted   $ (1.26 )   $ 4.12  
Weighted average shares outstanding:            
Basic     46,703       48,281  
Diluted     46,703       48,424  

CAL-MAINE FOODS, INC. AND SUBSIDIARIES
FINANCIAL HIGHLIGHTS
(Unaudited)
(In thousands)
 
SUMMARY BALANCE SHEETS
         
    August 29, 2026   May 30, 2026
Assets            
Cash and short-term investments   $ 767,592   $ 924,057
Receivables, net     285,232     264,431
Inventories, net     394,690     375,265
Prepaid expenses and other current assets     24,379     17,789
Current assets     1,471,893     1,581,542
             
Property, plant and equipment, net     1,312,285     1,318,335
Other noncurrent assets     229,201     207,693
Total assets   $ 3,013,379   $ 3,107,570
             
Liabilities and stockholders’ equity            
Accounts payable and accrued expenses   $ 191,127   $ 205,516
Current liabilities     191,127     205,516
             
Deferred income taxes and other liabilities     242,305     261,522
Stockholders’ equity     2,579,947     2,640,532
Total liabilities and stockholders’ equity   $ 3,013,379   $ 3,107,570
             

Contacts

Investors: ir@cmfoods.com 
Media: media@cmfoods.com 
Telephone: (601) 948-6813

SAN DIEGO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Beam Global (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for energy storage and security, electrification of mobility, and smart city infrastructure, will share developments in its advanced battery technologies for high-power applications, including AI data centers and electric aviation, during the Company’s presentations at The Battery Show North America, in Detroit, on October 12th through the 15th.

Beam Global is developing battery energy storage systems designed to manage the extreme power fluctuations generated by the rapidly increasing workloads of AI data centers. The research focuses on high-speed, multi-timescale control strategies that can reduce peak utility demand and required grid capacity while using less battery capacity than conventional approaches. The Company is also applying its proprietary passive thermal management technology to support frequent, high-rate battery cycling while managing battery temperatures and degradation.

Beam Global is evaluating its proprietary solutions to address thermal runaway initiation and propagation in high-power and high-energy lithium-ion battery systems for applications including electric vertical takeoff and landing (eVTOL) aircraft. Testing includes side and bottom nail penetration, external heating and overcharge to evaluate thermal and electrical behavior during cell failure. At the module level, Beam’s engineering and science teams are evaluating how battery architecture, enclosure design, thermal coupling, liquid-cooled cold plates and Beam’s phase-change composite (PCC™) technology affect cell-to-cell thermal propagation. Electro-thermal modeling is being used alongside physical testing to further characterize failure mechanisms and support the development of next-generation battery systems.

“Beam’s core competency and protected IP are centered on our ability to deliver high power bursts under extreme operating conditions using our superior engineering and proprietary thermal management solutions,” said Desmond Wheatley, CEO of Beam Global. “These capabilities are becoming increasingly essential for data centers and electric aviation applications like drones and eVTOLs. We are seeing significant increases in demand for our unique approach to these challenges. The Battery Show North America gives us the ideal opportunity to share the advances we are making to the very audiences who are seeking solutions to these critical challenges.”

Beam Global’s Chief Battery Scientist, Dr. Said Al-Hallaj, and Donald Gilmore, Director of Energy Storage Systems, will present preliminary findings from two of the Company’s research programs. Research into AI data center power transients will be presented by Donald Gilmore on October 13, followed by Dr. Said Al-Hallaj’s presentation on thermal runaway in drone and eVTOL battery systems on October 14. Both presenters will be available at Beam’s Booth 3403 for further discussion.

The markets for advanced battery technologies are expanding rapidly. According to MarketsandMarkets, the global data center energy storage systems market is projected to grow from $5.17 billion in 2026 to $10.48 billion by 2032, representing a 12.5% CAGR. The global eVTOL battery market is projected to grow from $6.90 billion in 2025 to $26.26 billion by 2032, representing a 21.0% CAGR, according to Fortune Business Insights.

About Beam Global

Beam Global is a sustainable technology innovator that develops and manufactures infrastructure products and technologies. The Company operates at the nexus of innovative and reliable energy, transportation and smart city solutions with a focus on sustainable energy infrastructure, rapidly deployed and scalable EV charging solutions, safe energy storage, energy security and intelligent infrastructure. With operations in the U.S., Europe and the Middle East, Beam Global develops, patents, designs, engineers and manufactures unique and advanced technology solutions that power transportation, provide secure sources of electricity, enable smart city services, save time and money, and protect the environment. Beam Global is headquartered in San Diego, CA, with facilities in Yuma, AZ; Broadview, IL; Belgrade and Kraljevo, Serbia; and Abu Dhabi, UAE. Beam Global is listed on Nasdaq under the symbol BEEM. For more information visit BeamForAll.com, LinkedIn, YouTube, Instagram and X.

Forward-Looking Statements

This Beam Global Press Release may contain forward-looking statements. All statements in this Press Release other than statements of historical facts are forward-looking statements. Forward-looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results. These statements relate to future events or future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Beam Global’s actual results to be materially different from these forward-looking statements. Except to the extent required by law, Beam Global expressly disclaims any obligation to update any forward-looking statements.

Investor Relations
Luke Higgins
+1 858-261-7646
IR@BeamForAll.com

Media Contact
Lisa Potok
+1 858-327-9123
Press@BeamForAll.com

Shentel Volunteers in action

Members of the Shentel team are volunteering and donating money to the Virginia Peninsula Foodbanks.
Members of the Shentel team are volunteering and donating money to the Virginia Peninsula Foodbanks.

EDINBURG, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) — Shenandoah Telecommunications Company (Shentel) (Nasdaq: SHEN) and its Glo Fiber brand have been awarded the prestigious 2026 CFX Top Ops Award for Community Relations, a distinction that recognizes broadband providers making a meaningful difference in the communities they serve. The award highlights Shentel’s commitment to delivering reliable broadband service while supporting local families, seniors, schools, and nonprofit organizations through employee volunteer efforts, charitable giving, and community partnerships.

“Connecting communities means more than just building networks,” said Heather Tormey, Vice President & Chief Human Resources Officer. “It means investing in the places we call home, supporting local organizations, and creating opportunities for people to thrive. This recognition reflects the dedication of our employees, who bring that commitment to life every day through their service, generosity, and engagement.”

At the heart of these efforts is the Shentel Cares Program which encourages employees to give back through volunteer service, community partnerships, and company-sponsored giving campaigns. Signature initiatives include Shentel Caring Days, the Summer Backpack Program, and The Big Give. Through eight volunteer events in the first half of 2026, employees have contributed more than 330 hours of service supporting organizations focused on food security, housing assistance, and other critical community needs.

The 2026 Summer Backpack Program raised $28,000 to support seven charitable organizations across Shentel’s service footprint through employee donations and matching contributions from the Shentel Foundation and CoBank’s Sharing Success program. These funds help provide food assistance and other essential resources to children and families in need. Building on this momentum, the company will soon launch its annual Big Give campaign, which empowers employees to support causes that are meaningful to them and their local communities.

The company’s commitment to community impact also extends beyond charitable giving. In June, the Glo Fiber Business team completed a major connectivity project at Friendship Richfield Living in Salem, Virginia, bringing high-speed fiber internet and entertainment services to more than 560 assisted living residences. To ensure residents could fully benefit from the new technology, team members hosted “Glo Fiber Days,” providing hands-on training and personalized support to help seniors confidently navigate their new digital tools and services.

“For more than a century, our success has been built on the relationships we’ve established in the communities we serve,” said Ed McKay, President and Chief Executive Officer for Shentel. “True community engagement goes well beyond financial support — it means showing up in person, getting our hands dirty alongside our team members, and supporting the local leaders and organizations making a daily impact. While we are committed to building quality broadband networks, we are equally focused on building lasting relationships with the people and communities we serve.”

To learn more about Shentel, please visit www.shentel.com for residential service and www.shentelbusiness.com for commercial service.

About Shenandoah Telecommunications
Shenandoah Telecommunications Company (Shentel) provides broadband services through its high-speed, state-of-the-art fiber optic and cable networks to residential and commercial customers in eight contiguous states in the eastern United States. Shentel’s services include broadband internet, video, voice, high-speed Ethernet, dark fiber leasing, and managed network services. The company owns an extensive regional network with more than 19,800 route miles of fiber. For more information, please visit www.shentel.com.

Media Contact:
Jennifer McDowell, Shentel
Jennifer.McDowell@emp.shentel.com
540-984-5055

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7ddcd938-8dd7-44f6-97e4-5bc7eaba0057

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — Namib Minerals (Nasdaq: NAMM) (“Namib Minerals” or the “Company”) today announced that it will release its financial results for the six months ended June 30, 2026, on Thursday, October 1, 2026, before the market opens. A conference call and webcast will follow at 8:30 AM ET the same day. Access details for the webcast will be announced shortly through the Investor Relations section of the Company’s website at www.namibminerals.com.

During the webcast, Namib Minerals’ management will respond to a selection of shareholders’ frequently asked questions submitted in advance of the call. Shareholders can submit questions through the Contact Us form at www.namibminerals.com.

The earnings release, webcast and presentation materials will be available in the Investor Relations section of www.namibminerals.com. A replay of the webcast will be available there shortly after the broadcast.

About Namib Minerals

Namib Minerals (Nasdaq: NAMM) is a gold producer, developer and explorer with operations focused in Zimbabwe. Namib Minerals is a significant player in Africa’s mining industry, driving sustainable growth and innovation across the sector. The Company currently operates How Mine, an underground gold mine, and is actively restarting Redwing Mine. For more information, visit www.namibminerals.com.

CONTACT: Contacts:
Lamiaa Maniar
VP of Communications
lmaniar@namibminerals.com

Transaction in Own Shares

September 29, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 29 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
29/09/2026 1,400,000 £ 36.3400 £ 35.7250 £ 35.9989 LSE GBP
29/09/2026 200,000 £ 36.1300 £ 35.7400 £ 35.9710 Chi-X (CXE) GBP
29/09/2026 – – – – BATS (BXE) GBP
29/09/2026 800,000 € 42.4700 € 41.7350 € 42.0546 XAMS EUR
29/09/2026 – – – – CBOE DXE EUR
29/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

Industrial and technology group CSG will participate in a major project to supply modern military equipment to the Latvian Armed Forces. The contractual documentation for the project was signed today. The project includes MORANA artillery systems, multiple rocket launcher systems, with a total value in the hundreds of millions of euros. The prime contractor for the project is TATRA DEFENCE SYSTEMS (TDS), a member of CSG. The project is based on extensive cooperation between the Czech, Slovak and Latvian defence industries, and financing through the European Security Action for Europe (SAFE) instrument is envisaged.

A key component of the project is the MORANA self-propelled howitzer, a joint Czech-Slovak defence industry product developed by CSG company EXCALIBUR ARMY in cooperation with Slovak defence industry partners. Key components are supplied by Slovak industry, including the 155 mm weapon system manufactured by ZŤS ŠPECIÁL. MORANA is a modern artillery system in the NATO-standard 155 mm calibre, mounted on a TATRA FORCE 8×8 chassis. The Latvian government has already decided to acquire Morana systems for the Latvian Armed Forces. According to the Latvian Ministry of Defence, the selection process took into account, among other factors, operational capabilities, costs, delivery schedules and opportunities for local defence industry participation.

In addition to the Morana howitzers, the project also envisages the delivery of multiple-launch rocket systems The use of a common Tatra vehicle platform will provide the Latvian Armed Forces with significant benefits in terms of logistics, maintenance, training and long-term lifecycle support.

A major element of the project is extensive industrial cooperation with the Latvian defence industry and the gradual localisation of production in Latvia. Some of the equipment will be manufactured in the Czech Republic and Slovakia, while other parts of the project are expected to involve manufacturing and final assembly directly in Latvia, supported by Czech and Slovak companies. The project is therefore designed not merely as a supply of military equipment, but as a long-term industrial partnership that will support the development of manufacturing, maintenance and other specialist capabilities within Latvia’s defence industry.

An important part of this cooperation will also be comprehensive maintenance and support for the supplied equipment throughout its entire lifecycle, with extensive involvement of Latvian industrial partners. The objective is to establish the capabilities in Latvia required for the long-term operation, maintenance and servicing of the supplied systems.

Raivis Melnis, Minister of Defence of Latvia, said: “The acquisition of new artillery and supporting systems represents an important step in further strengthening the capabilities of the Latvian Armed Forces. Equally important to us is the extensive involvement of Latvia’s defence industry in the implementation of this project. Our objective is not only to acquire modern military equipment, but also to develop domestic manufacturing, servicing and technological capabilities that will contribute to Latvia’s long-term resilience and security.”

Robert Kaliňák, Deputy Prime Minister and Minister of Defence of the Slovak Republic, said: “This project is a concrete example of how cooperation between European countries and their defence industries can deliver modern capabilities to our armed forces while strengthening Europe’s defence industrial base. The Slovak defence industry will play a significant role in the project and contribute technologically critical components to the systems. I am pleased that the framework established by Slovakia can facilitate broader cooperation with our partners and contribute to strengthening Europe’s defence capabilities.”

“The project for Latvia demonstrates how cooperation between European defence companies can contribute to the rapid strengthening of the capabilities of NATO and European Union member states. It brings together the technological and manufacturing capabilities of the Czech and Slovak defence industries with extensive involvement of Latvian partners. For CSG, it is also important that this is not simply about supplying equipment, but about establishing a long-term industrial partnership. The objective is to build manufacturing and maintenance capabilities in Latvia that will support the supplied equipment throughout its entire lifecycle,” said Jan Marinov, CEO of the CSG Defence Systems division.

Significant Role for the Slovak Defence Industry

The Slovak defence industry will also play an important role in the project, with Slovak companies responsible for some of the technologically critical elements of the systems to be supplied.

In the case of the Morana howitzer, the Slovak defence industry will participate in the supply of the 155 mm weapon system, the production of superstructures and other components, as well as the provision of the fire control system. The involvement of Slovak companies therefore represents a significant part of the project’s industrial supply chain. Internal project plans envisage the participation of Slovak industry specifically in these key areas.

Project Builds on an Existing Framework for European Cooperation

Tatra Defence Systems is the prime contractor for the project and has a framework agreement with the Slovak Ministry of Defence for the supply of Tatra Force military vehicles in a range of variants. The Czech Republic is also in discussions with the Slovak Ministry of Defence about joining this framework agreement. This mechanism enables the development of joint procurement of military equipment with the aim of achieving greater interoperability, a more efficient acquisition process and cooperation in providing lifecycle support for the equipment procured.

The project for Latvia has been designed with the European Security Action for Europe (SAFE) financial instrument in mind. SAFE supports investment by EU Member States in defence capabilities and joint European procurement of military equipment. The structure of the project also makes it possible to use the existing framework for the procurement of vehicles based on the Tatra Force platform.

The combination of the common Tatra platform, artillery and multiple-launch rocket systems, and the industrial capabilities of the Czech Republic, Slovakia and Latvia creates a strong basis for long-term cross-border cooperation within the European defence industry. Extensive involvement of Latvian partners in the manufacturing, assembly, maintenance and lifecycle support of the equipment is one of the key principles underpinning the planned project.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.